Addiction and schizophrenia: A translational perspective
Section snippets
Disclosure
In the past three years, Dr. Alan Green has received research grants from Alkermes, Novartis and Janssen, and he has also owned stock in Pfizer, Johnson & Johnson and Mylan. He has served as an (uncompensated) consultant to Otsuka and Alkermes, and as a member of a Data Monitoring Board for Lilly. Moreover, he is a co-inventor of one patent (and another patent application) regarding treatment of substance abuse. Dr. Khokhar does not have any conflicts to disclose.
Contributors
Drs. Khokhar and Green both conceptualized and wrote this Editorial.
Role of funding source
The authors are supported by grants from the National Institute of Drug Abuse (AIG; DA032533 and DA034699), from the National Center for Advancing Translational Science (AIG; NCATS UL1TR001086), from the National Institute on Alcohol Abuse and Alcoholism (JYK; K99AA025134) and by a Canadian Institute of Health Research Fellowship (JYK; MFE-140852).
Acknowledgments
We would like to thank all the contributors to this special issue and all the reviewers who helped improve the submissions with their valuable feedback.
References (43)
Schizophrenia: the fundamental questions
Brain Res. Brain Res. Rev.
(2000)- et al.
Patterns of substance abuse in schizophrenia: nature and significance
J. Psychiatr. Res.
(1994) - et al.
Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study
Schizophr. Res.
(2012) - et al.
Dysfunction of ventral striatal reward prediction in schizophrenia
NeuroImage
(2006) - et al.
Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia
Schizophr. Res.
(2017) - et al.
An analysis of the rewarding and aversive associative properties of nicotine in the neonatal quinpirole model: effects on glial cell line-derived neurotrophic factor (GDNF)
Schizophr. Res.
(2017) - et al.
Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders
Schizophr. Bull.
(2006) - et al.
Clozapine, olanzapine, or typical antipsychotics for alcohol use disorder in patients with schizophrenia
J. Dual Diagn.
(2008) - et al.
Demographic and clinical correlates of substance use disorders in first episode psychosis
Schizophr. Res.
(2017) - et al.
Psychiatric comorbidities and schizophrenia
Schizophr. Bull.
(2009)
Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population
Schizophr. Res.
The interaction of gender and cannabis in early phase psychosis
Schizophr. Res.
Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care
Am. J. Public Health
The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia
Schizophr. Bull.
Acquisition of nicotine self-administration in amphetamine and phencyclidine models of schizophrenia: a role for stress?
Schizophr. Res.
Pharmacotherapy for schizophrenia and co-occurring substance use disorders
Neurotox. Res.
Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?
Harv. Rev. Psychiatry
Schizophrenia and co-occurring substance use disorder
Am. J. Psychiatry
Comorbidity of severe psychotic disorders with measures of substance use
JAMA Psychiat.
Genetic correlation between smoking behaviors and schizophrenia
Schizophr. Res.
Psychosis reactivity to cannabis use in daily life: an experience sampling study
Br. J. Psychiatry
Cited by (11)
Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis
2018, Drug and Alcohol DependenceCitation Excerpt :Schizophrenia and related psychoses account for high levels of morbidity and are among the most misunderstood, neglected and stigmatized of all medical illnesses. One person in every hundred is likely to develop a schizophrenic disorder, and about half of these will have a substance use disorder (SUD) (Degenhardt and Hall, 2001; Green and Khokhar, 2018; McMillan et al., 2009; Regier et al., 1990). Persistent use of alcohol or illicit drugs has been reported to have adverse consequences for patients with schizophrenia that worsen the overall course and is associated with increased morbidity and mortality.
Dual disorder: does expert clinical experience support the rationale for cariprazine use?
2024, European Review for Medical and Pharmacological SciencesPsychotic Disorders and Substance Abuse Comorbidity: Characteristics and Treatment
2022, Psychosis and Personality Disorders: Unmet Needs in Early Diagnosis and Treatment